References
- Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis–clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129:154–162.
- Stevenson V, Gras A, Bardos J, et al. The high cost of spasticity in multiple sclerosis to individuals and society. Mult Scler. 2015;21:1583–1592.
- Zettl UK, Henze T, Essner U, et al. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Econ. 2014;15:953–966.
- Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24:593–604.
- Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.
- Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil. 2010;24:293–304.
- Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13:55–59.
- Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol. 2014;122:513–562.
- Sativex® Oromucosal Spray. UK/H/2462/001/DC, UK licence no: PL 18024/0009. Public Assessment Report. Decentralised Procedure. 2010 [cited 2015 May 5]. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con084961.pdf
- Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex (®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122–1131.
- Moreno Torres I, Sanchez AJ, Garcia-Merino A. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Rev Neurother. 2014;14:1243–1250.
- Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler. 2012;18:219–228.
- Notcutt WG. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim Health Care Res Dev. 2013;14:192–199.
- Meuth SG, Vila C, Dechant KL. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother. 2015;15:909–918.
- StatsWales: detailed official data on Wales [Internet]. 2011. [cited 2015 May 12]. Available from: https://statswales.wales.gov.uk/Catalogue/Health-and-Social-Care/Births-Deaths-and-Conceptions/Deaths/Deaths-by-Cause.
- Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev Pharmacoecon Outcomes Res. 2011;11:205–213.
- GW Pharma Ltd. UK Registry data: Sativex® GWSR10128. Report of data collection period 6 - 16 June 2010–28 October 2013. Report No.: GW-2014-02. 2014.
- NHS reference costs 2012 to 2013 [Internet]. 2013. [cited 2015 May 5]. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013.
- Personal Social Services Research Unit: unit costs of health and social care 2013 [Internet]. 2013 [cited 2015 May 5]. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2013/.
- British National Formulary: March 2014 edition [Internet]. 2014. [cited 2015 May 5]. Available from: http://www.pharmpress.com/mailouts/bnf/mar14/BNF_enewsletter.html
- Manouchehrinia A, Tanasescu R, Tench CR, et al. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry. 2015. doi:10.1136/jnnp-2015-310361
- Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85:240–247.
- Ragonese P, Aridon P, Salemi G, et al. Mortality in multiple sclerosis: a review. Eur J Neurol. 2008;15:123–127.
- All Wales Medicines Strategy Group - Form B guidance notes. 2015 [cited 2015 Jun 30]. Available from: www.awmsg.org/industry_form_b.html
- Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand. 2014;129:13–20.
- Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–595.
- Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012;12:439–441.
- Slof J, Ruiz L, Vila C. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):379–391.
- Lu L, Pearce H, Roome C, et al. Cost effectiveness of oromucosal cannabis-based medicine (Sativex(R)) for spasticity in multiple sclerosis. Pharmacoeconomics. 2012;30:1157–1171.
- Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev Neurother. 2013;13:15–19.